PRESS RELEASE:
FDA Regulatory and Compliance Symposium Features Special Sessions Managing Risks in Pharmacovigilance
  • Managing Risks - From Pipeline to Patient
  • August 22 - 25, 2006
  • Classes Held in Harvard University's Annenberg Hall and Sanders Theatre, Cambridge, MA
  • Symposium Hotels: The Charles Hotel, Cambridge, MA
  • www.FDASymposium.com
PRESS RELEASE
Phone: 800-684-4549
Email: registration@hcconferences.com
Website: www.FDASymposium.com

CAMBRIDGE, MA USA -- PHARMA UPDATE NEWS SERVICE(TM) -- JUNE 28, 2006: The Second FDA Regulatory and Compliance Symposium, www.FDASymposium.com, August 22 - 25, 2006, in Cambridge, MA announced today that it will feature special sessions on Advertising, Promotion and Compliance.

ADVERTISING, PROMOTION AND COMPLIANCE:

On Thursday, Aug. 24, 2006, the FDA Symposium will feature the following sessions:

8:00 a.m. Overview of Managing Risks in Pharmacovigilance

John Kamp, JD, Ph.D.
Executive Director, Coalition for Healthcare Communication
Of Counsel, Wiley Rein & Fielding LLP
(Co-chair)

Wayne Pines
President, Regulatory Services and Healthcare, APCO Worldwide
Former Associate Commissioner for Public Affairs, FDA
Washington, DC
(Co-chair)


8:15 a.m. Moving from DTC to DTC Squared: Direct-to-Patient Communications in the 21st Century

Peter Pitts
President, Center for Medicines in the Public Interest
Senior Vice President for Global Health Affairs, Manning, Selvage & Lee
Former Associate Commissioner for External Relations, FDA
New York, NY

9:00 a.m. Meeting the Latest FDA and OIG/DOJ Marketing Rules

Wayne Pines
President, Regulatory Services and Healthcare, APCO Worldwide
Former Associate Commissioner for Public Affairs, FDA
Washington, DC

9:45 a.m. Pharma Funding, Fraud and the First Amendment: A Critical View of Recent Federal Enforcement Actions

John Kamp, JD, Ph.D.
Executive Director, Coalition for Healthcare Communication
Of Counsel, Wiley Rein & Fielding LLP
Washington, DC

11:00 a.m. Innovative Models of Compliance Education: The 'Intellinex' Case Study

Jeffrey Lenow, MD, JD, FAAFP
Associate Professor, Department of Family and Community Medicine
Jefferson Medical College of Thomas Jefferson University
EVP, Chief Medical Officer, CardinalHealth
Medford, NJ

11:45 a.m. The Most Important Element to Assure That Your Sales and Marketing Compliance Program Is Working Effectively

Kelly Freeman, Ph.D.
Director, Compliance and Ethics
Eli Lilly and Company
Indianapolis, IN


GOVERNMENT KEYNOTE SPEAKERS:
Thomas W. Abrams, RPh, MBA
Director, Division of Drug Marketing, Advertising, and Communications, CDER, FDA, Washington, DC
Peter B. Bach, MD, MAPP
Senior Advisor, Office of the Administrator, Centers for Medicare & Medicaid Services, Washington, DC
Sheldon T. Bradshaw, Esq.
Chief Counsel, FDA, Washington, DC
Igor Cerny, Pharm.D.
Director, Advisors and Consultants Staff, Office of Executive Programs, Center for Drug Evaluation and Research, FDA, Washington, DC
Jon E. Clark
Associate Director for Policy Development and GMP, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Washington, DC
Scott Gottlieb, MD
Deputy Commissioner for Medical and Scientific Affairs, Office of the Commissioner, FDA, Washington, DC
David J. Horowitz, Esq.
Deputy Associate Commissioner for Compliance Policy, Office of Regulatory Affairs, FDA, Washington, DC
CAPT Paul J. Seligman, MD, MPH
Associate Director for Safety Policy and Communication, Center for Drug Evaluation and Research, FDA, Silver Spring, MD
James Sheehan, Esq.
Associate United States Attorney, U.S. Attorney's Office for the Eastern District of Pennsylvania, Philadelphia, PA

KEYNOTE SPEAKERS:
Jane E. Henney, MD
Senior Vice President and Provost for Health Affairs, University of Cincinnati Academic Health Center; Former Commissioner, FDA, Cincinnati, OH
Philip J. Hilts
Former Science Reporter, The New York Times and The Washington Post; Lecturer, Department of Journalism, Boston University; Author, Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation and RX for Survival: Why We Must Rise to the Global Health Challenge; Winner, 2004 Los Angeles Times Book Prize for Science and Technology and The New York Times Notable Book of the Year distinction, Brookline, MA
John F. Kamp, J.D., Ph.D.
Executive Director, Coalition for Healthcare Communication; Of Counsel, Wiley Rein & Fielding LLP, Washington, DC
Wayne L. Pines
President, Regulatory Services and Healthcare, APCO Worldwide; Former Associate Commissioner for Public Affairs, FDA, Washington, DC
Peter J. Pitts
President, Center for Medicines in the Public Interest; Senior Vice President for Global Health Affairs, Manning, Selvage & Lee; Former Associate Commissioner for External Relations, FDA, New York, NY
Eric J. Topol, MD
Professor, Department of Genetics, Case Western Reserve University, Cleveland, OH
Daniel E. Troy, Esq.
Partner, Sidley Austin Brown & Wood; Former Chief Counsel, Office of the General Counsel, FDA, Washington, DC

Arthur Miller, Esq.
Bruce Bromley Professor of Law
Harvard Law School
Cambridge, MA

"It is my pleasure to welcome attendees of the FDA Symposium to the campus of Harvard University. I hope that you will take advantage of this unique experience to study key Food and Drug Administration regulatory and compliance issues in this extraordinary academic environment."


SYMPOSIUM OVERVIEW:

Rarely have there been so many major changes and uncertainties with such far-reaching consequences to drug development, manufacturing, monitoring and marketing. And rarely has there been a greater need to bring together representatives and advisors from government and the world's leading drugmakers to share strategies for regaining consumer confidence in today's medicines.

The FDA Regulatory and Compliance Symposium-a unique three-day, high-level forum in one of the world's most famous academic settings-will help drugmakers prepare for the full impact of all the changes flowing from the FDA and Congress, while clarifying many of the uncertainties. The Symposium will also provide practical, state-of-the-art solutions to the challenges of eliminating or reducing risks throughout the product life-cycle-from the drug pipeline to manufacturing to patient delivery.

The Symposium takes place on the campus of Harvard University. Classes are held in Annenberg Hall of the Sanders Theatre Complex. Inspired by the great halls of Oxford and Cambridge Universities, this room is arguably the most impressive space at Harvard. Harvard University, the oldest institution of higher learning in the United States, was established in 1636. Today, Harvard has grown to become a great undergraduate and graduate research university.

SPONSORED BY:






EXHIBIT & SPONSORSHIP INFORMATION:
J.T. Hroncich
300 N. Washington St., Suite 200
Falls Church, VA 22046
Phone: (703) 538-7643
Fax: (703) 538-7007
E-mail: jhroncich@fdanews.com
Joni Lipson
100 North 20th Street, 4th Floor
Philadelphia, PA 19103
Phone: (800) 546-3750
Fax: (215) 545-8107
E-mail: joni.lipson@rmpinc.com


REGISTRATION INFORMATION:

For further registration information, go to www.fdasymposium.com/registration.html, call 800-684-4549, email registration@hcconferences.com or write:

FDA Symposium Office
7790 Barberry Ave.
Yucca Valley CA USA 92284